Human papillomavirus (HPV) is associated with cervical cell changes, genital warts, recurrent respiratory papillomatosis, laryngeal papillomatosis, head and neck cancer, and cervical cancer. Two commercial HPV vaccines have successfully been made available in the clinical field. This review covers the progress of cervical disease by understanding the nature of HPV infection, as well as the relationship between the host factors and HPV vaccine effectiveness. Among these host factors, microbiota has been revealed to influence the development and function of both the innate and adaptive immune systems. Therefore, the composition of the microbiome may ultimately affect vaccine efficacy. Understating the relationship between host factors and HPV infection/vaccine efficacy may prove to be useful in earlier diagnosis, as well as disease prophylaxis.
INTRODUCTION
Humans are constantly exposed to pathogenic microorganisms, including viruses, bacteria, and fungi. Among these microorganisms, human papillomavirus (HPV) is the most common sexually transmitted infection worldwide (1) .
Currently, two HPV commercial vaccines have been approved for use in the clinical field. These are termed 'Gardasil' and 'Cervarix', which cover 4 (6, 11, 16 and 18) and 2 (16 and 18) HPV types, respectively (2) . In December 2014, Gardasil 9 was approved in the USA, which covers 9 HPV types (6, 11, 16, 18, 31, 33, 45, 52 , and 58) (3). The characters of these HPV vaccines are summarized in Table   1 . While the mechanism of HPV infection and the subsequent development of cervical cancers have been extensively studied, there are many unknowns in the relationship between the host factors (e.g. genetic polymorphism, microbiome, disease status, and immune system) and HPV vaccine effectiveness. Among the various host factors affecting vaccine efficacy, the role of the microbiome has now been established (4, 5) . In this review, we will summarize the recent data on the relationship between the host factors, especially microbiota composition, and both HPV vaccine efficacy and HPV infection.
Basics of HPV infection
HPV is a circular double-stranded DNA (dsDNA) virus for which more than 200 different types have been identified and categorized into high-and low risk (6) . HPV has a nonenveloped, icosahedral capsid, and infects only mucosal or cutaneous epithelium (7) . The fifteen types of HPV classified as high risk include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 (8) . In particular, HPV 16 and 18 are known to cause up to 70% of cervical cancers (9) . The low risk HPV types include types 6, 11, 42, 43, and 44, which are involved in the development of cervical cell changes, genital warts, recurrent respiratory papillomatosis, and laryngeal papillomatosis (10~12).
Cervical cancer, the second most prevalent cancer among women, is associated with HPV infection (13) . To detect potentially dangerous HPV strains and to defend against infection, humans have developed effective innate and adaptive immune systems that minimize the impact of pathogens on human health. On the other hand, HPV uses specific life strategies to enable its survival and persistence within the epithelial cells, including diverse mechanisms to evade host immune surveillance via programming for natural cell death, which causes the progeny virions only to be released in high quantities from terminally differentiated epithelial cells (14) . HPV infects only mucosal or cutaneous epithelium. In addition, HPV induces a slow and weak immune response, which inhibits interferon synthesis (15, 16) .
The HPV genome encodes two structural capsid proteins (L1 and L2) and three oncoproteins (E5, E6 and E7) (17, 18) . The major capsid protein L1 self-assembles into viruslike particles (VLPs), which are in tertiary or native form and are assembled as multimers to generate neutralizing antibodies. HPV L1 VLP vaccines have been developed commercially (Table 1) . VLP vaccines are highly immunogenic and induce HPV neutralizing antibodies, which persist for at least 5 years after immunization. The HPV E5 protein suppresses the expression of MHC class I and antigen processing via the transporter associated with the antigen processing pathway (19, 20) . HPV E6 ubiquitinates (ubiquitin mediated degradation) the p53 tumor suppressor protein (21) , whereas E7 ubiquitinates the retinoblastoma (pRb) tumor suppressor protein (22) , indicating that these two proteins may have oncogenic effects. In addition, the HPV E6 protein causes downregulation of the expression of interferon-related genes and transcription factor NF-κB (23) . NF-κB activates a local immune response (e.g., MHC class I, interleukins and GM-CSF) and an IFN-β promoter (24) . Inhibition of NF-κB may help the HPV virus to escape immune recognition. The HPV E7 protein blocks cell cycle regulatory genes are required for G1/S transition and DNA replication. These proteins (E5, E6 and E7) are also able to break antigen presentation (25) (Fig. 1) . Therefore, these three proteins also play roles in the evasion of the innate and adaptive immune system, which creates a favorable (27) .
Factors affecting HPV infection and vaccine
Many factors affect HPV infection, including sex, estrogen hormones, microbiome, genetics, epigenetic phenomena, age, nutrition, immune system, and infectious and autoimmune diseases (28, 29).
Impact of host genetic factors on HPV infection
Population based association studies (genetic polymor- . HPV infection into a host tissue leads to oncogenic processes. HPV E5 protein suppresses the expression of MHC class I and antigen processing. HPV E6 protein binds p53 tumor suppressor protein and this binding blocks p53 defense mechanisms, as well as p53-induced antiviral activity (down-regulates the expression of the antiviral interferon-related genes and the transcription factor NF-κB), through cell cycle arrest and apoptosis of the infected cell by degradation of p53 via ubiquitination. HPV E7 protein binds pRb cell cycle regulatory protein, which can block cell cycle arrest by degradation of Rb via ubiquitination. Therefore, these proteins play roles in tumor promotion. These HPV E5, E6, and E7 proteins are able to impair the innate and acquired immune response, which play roles in the evasion of the host immune system. MHC class I, major histcompatibility complex class I; pRb, retinoblastoma protein; Ag, antigen; IFN, interferon gamma; NF-κB, nuclear factor-κB.
Moreover, polymorphism in the proinflammatory cytokine gene Tumor necrosis factor-α (TNF-α) also causes increased the risk of HPV associated cervical cancer in the presence of HPV. TNF-α-308 G/A polymorphism may play a role in TNF-α production and the inflammatory response during the course of cervical cancer. In particular, the A allele is associated with an increased risk of invasive cervical cancer (32, 33) . Individuals with the TNF-α-308 G/A and -238 G/A promoter genotypes are at increased risk of developing inflammatory, infectious and autoimmune disease (33) .
These results suggest that host genetic polymorphisms can influence the nature and extent of HPV-mediated disease.
Impact of host microbiome on metabolic disorder and chronic inflammatory disease
The interplay between HPV, the gut epithelium, and host innate defense responses is among the most critical factors determining the fate of HPV infections and disease outcomes. Recently, gut microbiota were found to contribute to many host physiological processes and disease (34, 35) . (57) (Fig. 2) . However, Tlr5-/-mice exhibit similar changes in the microbiota shape as ob/ob mice (leptin gene deficiency). The Tlr5-/-phenotype is due to changes in the microbiota, causing hyperphagia and metabolic syndromes, including insulin resistance, hyperlipidemia, and obesity (43) . TLR9 recognizes the viral or bacterial dsDNA derived CpG motifs, but its transcription is inhibited by recombinant HPV 16 E6 and E7 (26) . 
Nod2
-/-mice are susceptible to pathogen infection because of an intrinsic defect in their ability to kill the bacteria. In addition, these mice also have increased populations of commensal bacteria in the intestine, suggesting that NOD2 plays a crucial role in regulating homeostasis between bacterial flora and innate immunity (64) . Moreover, NLRP6 deficient mice exhibited increased members of Prevotellaceae and TM7, and reduced members of Lactobacillus, which caused increased intestinal inflammatory cell recruit- LGG has an immunostimulatinq effect on rotavirus vaccination via enhance IgA production and release of interferon γ.
LGG or Lactococcus lactis (L. lactis)
Salmonella typhi Ty21a vaccine
LGG stimulated IgA sASC responses against S. typhi Ty21a. L. lactis has increase CR3 receptor expression on the neutrophils which can influence the non-specific immune response.
LGG towards increased serum IgG after administration of probiotics (69, 70) . However, probiotic formulations may not improve the response to a particular vaccine (71) . The recent data regarding the relationship between probiotic treatment and vaccine efficacy are summarized in Table 2 . Taken together, these data indicate that the effects of probiotics on vaccine efficacy may be dependent on the types of vaccines (69, 70, 72~77) . However, the detailed mechanisms urgently need to be revealed.
Meanwhile, healthy vaginal microbiota is composed primarily of lactic acid producing bacteria, which contribute to women's health by maintaining a low pH in the vagina (5) . Abnormal vaginal microbiota might act as a cofactor for the acquisition of HPV. Especially, L. gasseri and Gardnerella vaginalis were detected more frequently, along with a significantly higher diversity of the microbiota in HPV-infected women than in HPV negative women (78) .
Ultimately, the composition of the vaginal microbiota may affect HPV infection and disease progression.
CONCLUDING REMARKS
As mentioned above, HPV infection may be at least partially dependent on vaginal microbiota composition, whereas the efficacy of the HPV vaccine may be dependent on the intestinal microbiota composition. However, to the best of our knowledge, direct evidence for the relationship between HPV vaccine efficacy and microbiota composition
has not yet been provided. Therefore, research of the interaction between the host factors, especially microbiota, and HPV vaccine effectiveness is needed to enhance our understanding of the HPV-related disease, cervical cancer, and to guarantee its prevention.
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